The mechanism of action of BCG therapy for bladder cancer--a current perspective.
about
Immunobiology and immunotherapy in genitourinary malignanciesInhibiting Immune Checkpoints for the Treatment of Bladder CancerBacteria in Cancer Therapy: Renaissance of an Old ConceptThe role of mycobacterial cell wall nucleic acid complex in the treatment of bacillus Calmette-Guérin failures for non-muscle-invasive bladder cancerBladder Cancer Stem-Like Cells: Their Origin and Therapeutic PerspectivesManaging the adverse events of intravesical bacillus Calmette-Guérin therapyManagement of carcinoma in situ of the bladder: best practice and recent developmentsImmunostimulatory Gene Therapy Using Oncolytic Viruses as VehiclesTargeting Hsp90 in urothelial carcinomaMycobacteria emulsified in olive oil-in-water trigger a robust immune response in bladder cancer treatment.Prediction of Bacillus Calmette-Guerin Response in Patients with Bladder Cancer after Transurethral Resection of Bladder Tumor by Using Genetic Variation Based on Genomic StudiesThe Role of Toll-Like Receptors in Hematopoietic MalignanciesEZH2 in Bladder Cancer, a Promising Therapeutic TargetDeletion of F4L (ribonucleotide reductase) in vaccinia virus produces a selective oncolytic virus and promotes anti-tumor immunity with superior safety in bladder cancer models.Nonspecific effects of neonatal and infant vaccination: public-health, immunological and conceptual challenges.Cancer and the microbiota.Immunotherapy for bladder cancer.Systemic therapy for bladder cancer - a medical oncologist's perspective.Local checkpoint inhibition of CTLA-4 as a monotherapy or in combination with anti-PD1 prevents the growth of murine bladder cancer.Inoculation site from a cutaneous melanoma patient treated with an allogeneic therapeutic vaccine: a case report.Modelling bladder cancer in mice: opportunities and challenges.Mincle, an Innate Immune Receptor, Is Expressed in Urothelial Cancer Cells of Papillomavirus-Associated Urothelial Tumors of Cattle.The interplay of extracellular matrix and microbiome in urothelial bladder cancer.Manipulation of BCG vaccine: a double-edged sword.Microbiome, a new dimension in cancer researchDifferential Adverse Event Profiles Associated with BCG as a Preventive Tuberculosis Vaccine or Therapeutic Bladder Cancer Vaccine Identified by Comparative Ontology-Based VAERS and Literature Meta-AnalysisHigh CD4⁺ T cell density is associated with poor prognosis in patients with non-muscle-invasive bladder cancerHigh CD204+ tumor-infiltrating macrophage density predicts a poor prognosis in patients with urothelial cell carcinoma of the bladder.Mutated Fanconi anemia pathway in non-Fanconi anemia cancersEnglerin A induces an acute inflammatory response and reveals lipid metabolism and ER stress as targetable vulnerabilities in renal cell carcinomaPharmacogenomics: Biomarker-Directed Therapy for Bladder Cancer.Transient microbiota exposures activate dormant Escherichia coli infection in the bladder and drive severe outcomes of recurrent disease.Antiandrogen Therapy with Hydroxyflutamide or Androgen Receptor Degradation Enhancer ASC-J9 Enhances BCG Efficacy to Better Suppress Bladder Cancer Progression.Pathogen boosted adoptive cell transfer immunotherapy to treat solid tumors.Questions and challenges associated with studying the microbiome of the urinary tract.Spotlight on atezolizumab and its potential in the treatment of advanced urothelial bladder cancer.Insights into Local Tumor Microenvironment Immune Factors Associated with Regression of Cutaneous Melanoma Metastases by Mycobacterium bovis Bacille Calmette-Guérin.Cytokines as effectors and predictors of responses in the treatment of bladder cancer by bacillus Calmette-Guérin.Recombinant bacillus Calmette-Guérin in urothelial bladder cancer immunotherapy: current strategies.Immune therapies in non-muscle invasive bladder cancer.
P2860
Q26738668-864B1751-19F7-4D56-9720-790FB72C8B45Q26744758-E6CE3226-E82E-45F1-AA90-6C605107BD4BQ26751222-D68C33C3-FB88-49C7-BF04-13300D312B26Q26770422-87FD61DF-4E18-4E79-B0DD-A9055D36ED24Q26771263-E978D7E1-8DC6-433F-8EDE-D114EBBF90ECQ26775644-0D0DBC4F-7350-485C-92B8-BBAACF15DB75Q26775772-148C722E-B328-4C83-9287-97825E9E52D5Q26777403-7F29C3EC-E548-4823-B98B-6009F50B84E1Q27023406-24227726-30BB-469C-9D6F-58B9EDC05170Q27346705-0C1D270E-0122-466A-B009-FD6B15738A2AQ28076563-08EFFE9A-E18D-4F77-B1AA-9E8DF7CCD2FBQ28077740-C50ACE34-85AB-4AAD-B407-3E3B53B5373AQ28082054-918E39C8-0D05-4382-953F-FE7037A7BDCFQ33625843-F3633E64-C043-48C2-8F69-A5356CB60A13Q34439339-ED6705C1-7922-40EF-B884-3BCDD1EF7BCEQ34470083-8BDDD4C9-2C06-4659-B783-7930C5464EA4Q34477444-7E53216D-F919-4651-A13C-96186D6A7CB0Q34516731-95187C82-BC6C-4F9D-8096-DCAF108B4A2AQ34545316-25FA6A24-5597-4244-A342-289C982A5C95Q35229087-8F72C749-69F1-4C56-AC84-5015EDAAF3D0Q35285703-71E48720-24A2-4DC8-8185-8BD0937BA613Q35826351-69331783-7F76-44D7-B080-85B1A75D9357Q35868405-C102C073-536A-47FA-8F1D-9C7A491C0826Q35904315-799AE878-47FB-441E-B580-0172D10E88C8Q36138105-0CE9B576-99C6-418F-8CB6-812C5657983DQ36165332-BDA4E9FE-8B45-4A79-9768-BBC1A799B623Q36261897-FB3FF637-4554-4411-B19C-3F1D9FD38897Q36299634-13A38821-6E49-467F-9940-72A6C5A290C9Q36299696-57D410F6-AE76-479B-986E-D5116F6F599AQ36308931-32EE2B6F-401B-455C-B0E3-6014BAC57971Q36328010-C67DF51B-2ABC-462A-9233-E7986A5F37BEQ36328388-8BF4CEF9-87A1-44E2-A534-E39BC7B4DEDCQ36439816-F7114B10-611F-4F8C-B794-284D7D31421CQ37612527-78FB46F7-CDF1-4406-8D00-CD78FDAC5A44Q37634443-FDD1DBA5-CD4A-4249-9F05-5E02BD1BEBC4Q37702430-7E740AC9-E0D7-40B5-B1F0-9529D4900B1CQ37737540-CCD8AE84-3A32-41DE-87BC-9783CBA5E7E2Q38232854-0E867F13-8548-49EC-BC36-93474ECF58A9Q38251141-9593E258-95E8-4C1E-8530-EC4F4DBB9FFDQ38372571-FF922BE1-1745-40FF-AEBC-7AA5F3194630
P2860
The mechanism of action of BCG therapy for bladder cancer--a current perspective.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
The mechanism of action of BCG therapy for bladder cancer--a current perspective.
@en
type
label
The mechanism of action of BCG therapy for bladder cancer--a current perspective.
@en
prefLabel
The mechanism of action of BCG therapy for bladder cancer--a current perspective.
@en
P2860
P356
P1476
The mechanism of action of BCG therapy for bladder cancer--a current perspective.
@en
P2093
Gil Redelman-Sidi
Michael S Glickman
P2860
P2888
P304
P356
10.1038/NRUROL.2014.15
P407
P577
2014-02-04T00:00:00Z
P6179
1002890025